Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma

Inclusion Criteria: * Mild stable allergic asthma * Positive skin-prick test to at least one common aeroallergen * Positive methacholine challenge * Positive allergen-induced early- and late-phase airway bronchoconstriction * General good health Exclusion Criteria: * Lung diseases other than mild allergic asthma * History or symptoms of cardiovascular disease, significant neurologic disease, and/or clinically significant autoimmune disease * Chronic use of asthma medications other than short or intermediate beta-agonists or ipratropium * Use of tobacco products within one year starting study or smoking history \>10 pack years * If female, pregnant or lactating or have positive pregnancy test at screening